Hilkka Soininen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3729551/publications.pdf

Version: 2024-02-01

309 papers 27,404 citations

67 h-index

13854

7511 151 g-index

337 all docs

337 docs citations

times ranked

337

30600 citing authors

#	Article	IF	CITATIONS
1	The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). Alzheimer's and Dementia, 2022, 18, 1325-1334.	0.4	24
2	S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of Disease, 2022, 163, 105603.	2.1	4
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
4	Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial. European Heart Journal, 2022, 43, 2054-2061.	1.0	26
5	Occupational complexity and cognition in the FINGER multidomain intervention trial. Alzheimer's and Dementia, 2022, 18, 2438-2447.	0.4	4
6	Psychosocial determinants for adherence to a healthy lifestyle and intervention participation in the FINGER trial: an exploratory analysis of a randomised clinical trial. Aging Clinical and Experimental Research, 2022, 34, 1793-1805.	1.4	5
7	Associations of Depressive Symptoms and Cognition in the FINGER Trial: A Secondary Analysis of a Randomised Clinical Trial. Journal of Clinical Medicine, 2022, 11, 1449.	1.0	1
8	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
9	Factors Predicting Engagement of Older Adults With a Coach-Supported eHealth Intervention Promoting Lifestyle Change and Associations Between Engagement and Changes in Cardiovascular and Dementia Risk: Secondary Analysis of an 18-Month Multinational Randomized Controlled Trial. Journal of Medical Internet Research. 2022. 24. e32006.	2.1	22
10	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
11	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
12	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63
13	Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 491-498.	1.7	11
14	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1,2	5
15	Regional Strength of Large-Scale Functional Brain Networks is Associated with Regional Volumes in Older Adults and in Alzheimer's Disease. Brain Connectivity, 2021, 11, 201-212.	0.8	8
16	Earlier life leisure-time physical activity in relation to age-related frailty syndrome. Age and Ageing, 2021, 50, 161-168.	0.7	7
17	36â€month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 29-40.	0.4	77
18	Obesity and Brain Vulnerability in Normal and Abnormal Aging: A Multimodal MRI Study. Journal of Alzheimer's Disease Reports, 2021, 5, 65-77.	1,2	11

#	Article	IF	Citations
19	Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index. Alzheimer's and Dementia, 2021, 17, 1205-1212.	0.4	23
20	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	3.8	49
21	5-Year health-related quality of life outcome in patients with idiopathic normal pressure hydrocephalus. Journal of Neurology, 2021, 268, 3283-3293.	1.8	5
22	27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 56.	3.0	18
23	A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 63.	3.0	3
24	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	3.0	6
25	Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1407-1414.	1.7	17
26	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
27	Effect of a Multidomain Lifestyle Intervention on Estimated Dementia Risk. Journal of Alzheimer's Disease, 2021, 82, 1461-1466.	1.2	16
28	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
29	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 20.	3.0	60
30	The association between diabetes and Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
31	Multimodal preventive trial for Alzheimer's disease (MINDâ€AD _{MINI}): Pilot trial progress and results. Alzheimer's and Dementia, 2021, 17, .	0.4	0
32	Occupational complexity and neuroimaging measures of structural MRI and PETâ€amyloid in a randomized controlled trial: FINGER. Alzheimer's and Dementia, 2021, 17, .	0.4	0
33	Lifestyle and behavior changes during the COVID19 pandemic in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2021, 17, .	0.4	0
34	Engagement with a preventive eHealth intervention in older adults (the HATICE trial): Predictive factors and associations with dementia and cardiovascular risk. Alzheimer's and Dementia, 2021, 17, .	0.4	0
35	Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. Molecular Psychiatry, 2020, 25, 1859-1875.	4.1	191
36	Longâ€term dementia risk prediction by the LIBRA score: A 30â€year followâ€up of the CAIDE study. International Journal of Geriatric Psychiatry, 2020, 35, 195-203.	1.3	36

3

#	Article	IF	CITATIONS
37	Midlife improvements in financial situation are associated with a reduced dementia risk later in life: the CAIDE 30-year study. International Psychogeriatrics, 2020, 32, 1317-1324.	0.6	3
38	White Matter Changes on Diffusion Tensor Imaging in the FINGER Randomized Controlled Trial. Journal of Alzheimer's Disease, 2020, 78, 75-86.	1.2	17
39	Third follow-up of the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) cohort investigating determinants of cognitive, physical, and psychosocial wellbeing among the oldest old: the CAIDE85+ study protocol. BMC Geriatrics, 2020, 20, 238.	1.1	8
40	Presynaptic Vesicle Protein SEPTIN5 Regulates the Degradation of APP C-Terminal Fragments and the Levels of $A\hat{l}^2$. Cells, 2020, 9, 2482.	1.8	8
41	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	5.8	26
42	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	1.5	51
43	Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline. Frontiers in Aging Neuroscience, 2020, 12, 228.	1.7	9
44	Diabetes is associated with familial idiopathic normal pressure hydrocephalus: a case–control comparison with family members. Fluids and Barriers of the CNS, 2020, 17, 57.	2.4	6
45	Production of Inflected Novel Words in Older Adults With and Without Dementia. Cognitive Science, 2020, 44, e12879.	0.8	2
46	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
47	Dementia risk scores as surrogate outcomes for lifestyleâ€based multidomain prevention trials—rationale, preliminary evidence and challenges. Alzheimer's and Dementia, 2020, 16, 1674-1685.	0.4	18
48	The impact of a nutritional intervention in prodromal Alzheimer's disease: The LipiDiDiet clinical trial. Alzheimer's and Dementia, 2020, 16, e039846.	0.4	0
49	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	0
50	Change in CAIDE dementia risk score and neuroimaging biomarkers during a 2â€year multidomain lifestyle randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e040879.	0.4	0
51	Impact of baseline impaired sleep, depressive symptoms and pain on physical activity in the FINGER multidomain lifestyle trial. Alzheimer's and Dementia, 2020, 16, e041462.	0.4	0
52	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.4	1
53	Effect of berries and fruits on cognitive change during a 2â€year multiâ€domain lifestyle intervention: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2020, 16, e042431.	0.4	1
54	Research diagnostic criteria for Alzheimer's disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530.	0.4	0

#	Article	IF	Citations
55	Differential diagnosis of dementia combining webâ€based cognitive testing and MRI. Alzheimer's and Dementia, 2020, 16, e042626.	0.4	0
56	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. Alzheimer's and Dementia, 2020, 16, e042687.	0.4	0
57	Suitability of dementia risk scores as surrogate outcomes for lifestyleâ€based multidomain prevention trials. Alzheimer's and Dementia, 2020, 16, e042798.	0.4	О
58	Longâ€term dietary intervention adherence among individuals with elevated risk of dementia: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2020, 16, e045150.	0.4	0
59	The reliability of a deep learning model in external memory clinic MRI data: A multiâ€cohort study. Alzheimer's and Dementia, 2020, 16, e042969.	0.4	0
60	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	1.6	30
61	Lateâ€life personality traits, cognitive impairment, and mortality in a populationâ€based cohort. International Journal of Geriatric Psychiatry, 2020, 35, 989-999.	1.3	5
62	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	7.0	90
63	Pooling individual participant data from randomized controlled trials: Exploring potential loss of information. PLoS ONE, 2020, 15, e0232970.	1.1	2
64	Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial. BMC Geriatrics, 2020, 20, 99.	1.1	28
65	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	1.2	13
66	Association of Peripheral Insulin Resistance and Other Markers of Type 2 Diabetes Mellitus with Brain Amyloid Deposition in Healthy Individuals at Risk of Dementia. Journal of Alzheimer's Disease, 2020, 76, 1243-1248.	1.2	17
67	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.4	257
68	Biomarker validation of a dementia risk prediction score. Nature Reviews Neurology, 2020, 16, 135-136.	4.9	4
69	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	1.1	7
70	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 277-286.	1.2	13
71	Cardiovascular health metrics from mid- to late-life and risk of dementia: A population-based cohort study in Finland. PLoS Medicine, 2020, 17, e1003474.	3.9	44
72	Attitudes of at-risk older adults about prevention of cardiovascular disease and dementia using eHealth: a qualitative study in a European context. BMJ Open, 2020, 10, e037050.	0.8	4

#	Article	IF	CITATIONS
73	Title is missing!. , 2020, 17, e1003474.		O
74	Title is missing!. , 2020, 17, e1003474.		0
75	Title is missing!. , 2020, 17, e1003474.		0
76	Title is missing!. , 2020, 17, e1003474.		0
77	Title is missing!. , 2020, 17, e1003474.		0
78	Title is missing!. , 2020, 17, e1003474.		0
79	Title is missing!. , 2020, 17, e1003474.		0
80	Title is missing!. , 2020, 15, e0226784.		0
81	Title is missing!. , 2020, 15, e0226784.		0
82	Title is missing!. , 2020, 15, e0226784.		0
83	Title is missing!. , 2020, 15, e0226784.		0
84	Prevalence of Schizophrenia in Idiopathic Normal Pressure Hydrocephalus. Neurosurgery, 2019, 84, 883-889.	0.6	15
85	Computer-based cognitive training for older adults: Determinants of adherence. PLoS ONE, 2019, 14, e0219541.	1.1	52
86	Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimer's disease with Fortasyn Connect. BMC Medical Research Methodology, 2019, 19, 163.	1.4	5
87	Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients. Journal of Alzheimer's Disease, 2019, 72, 127-137.	1.2	13
88	The Association Between Distinct Frontal Brain Volumes and Behavioral Symptoms in Mild Cognitive Impairment, Alzheimer's Disease, and Frontotemporal Dementia. Frontiers in Neurology, 2019, 10, 1059.	1.1	37
89	Understanding the effect of cognitive/brain reserve and depression on regional atrophy in early Alzheimer's disease. Postgraduate Medicine, 2019, 131, 533-538.	0.9	11
90	Self and Informant Memory Reports in FINGER: Associations with Two-Year Cognitive Change. Journal of Alzheimer's Disease, 2019, 71, 785-795.	1.2	5

#	Article	lF	Citations
91	Predicting Development of Alzheimer's Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 71, 1233-1243.	1.2	28
92	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
93	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid- \hat{l}^2 Load in Subjects Examined for Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 67, 1343-1351.	1.2	13
94	Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study. Alzheimer's Research and Therapy, 2019, 11 , 11 .	3.0	37
95	Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's Research and Therapy, 2019, 11, 53.	3.0	75
96	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
97	Altered frontal and insular functional connectivity as pivotal mechanisms for apathy in Alzheimer's disease. Cortex, 2019, 119, 100-110.	1.1	27
98	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. Alzheimer's and Dementia, 2019, 15, 729-741.	0.4	68
99	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	3.0	23
100	Cardiorespiratory Fitness and Cognition: Longitudinal Associations in the FINGER Study. Journal of Alzheimer's Disease, 2019, 68, 961-968.	1.2	38
101	Prevalence of <i>C9ORF72</i> Expansion in a Large Series of Patients with Idiopathic Normal-Pressure Hydrocephalus. Dementia and Geriatric Cognitive Disorders, 2019, 47, 91-103.	0.7	9
102	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	2.3	23
103	Detecting frontotemporal dementia syndromes using MRI biomarkers. NeuroImage: Clinical, 2019, 22, 101711.	1.4	35
104	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	0.7	23
105	The Effect of Multidomain Lifestyle Intervention on Daily Functioning in Older People. Journal of the American Geriatrics Society, 2019, 67, 1138-1144.	1.3	35
106	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
107	Integrating nurses' experiences with supporting behaviour change for cardiovascular prevention into a self-management internet platform in Finland and the Netherlands: a qualitative study. BMJ Open, 2019, 9, e023480.	0.8	10
108	Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. The Lancet Digital Health, 2019, 1, e424-e434.	5.9	83

#	Article	IF	Citations
109	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
110	A multiomic approach to characterize the temporal sequence in Alzheimer's disease-related pathology. Neurobiology of Disease, 2019, 124, 454-468.	2.1	41
111	Brain \hat{l}^2 -Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline. American Journal of Neuroradiology, 2019, 40, 80-85.	1.2	10
112	Effects of morphological family on word recognition in normal aging, mild cognitive impairment, and Alzheimer's disease. Cortex, 2019, 116, 91-103.	1,1	7
113	Dietary changes and cognition over 2 years within a multidomain intervention trialâ€"The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2019, 15, 410-417.	0.4	63
114	Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. Journal of the American Medical Directors Association, 2019, 20, 843-849.e5.	1.2	28
115	Serum Insulin and Cognitive Performance in Older Adults: A Longitudinal Study. American Journal of Medicine, 2019, 132, 367-373.	0.6	14
116	Automatic MRI Quantifying Methods in Behavioral-Variant Frontotemporal Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 51-59.	0.6	19
117	Interrelationship between the Levels of C9orf72 and Amyloid- \hat{l}^2 Protein Precursor and Amyloid- \hat{l}^2 in Human CellsÂand Brain Samples. Journal of Alzheimer's Disease, 2018, 62, 269-278.	1.2	3
118	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	1.5	110
119	Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial. Journal of Alzheimer's Disease, 2018, 62, 649-663.	1.2	36
120	Incidence, Comorbidities, and Mortality in Idiopathic Normal PressureÂHydrocephalus. World Neurosurgery, 2018, 112, e624-e631.	0.7	37
121	Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. Journal of Alzheimer's Disease, 2018, 62, 165-174.	1.2	9
122	Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention. JAMA Neurology, 2018, 75, 462.	4.5	136
123	Sleep disturbances and later cognitive status: a multi-centre study. Sleep Medicine, 2018, 52, 26-33.	0.8	27
124	Cardiorespiratory fitness and risk of dementia: a prospective population-based cohort study. Age and Ageing, 2018, 47, 611-614.	0.7	24
125	Prevalence of the apolipoprotein E $\hat{l}\mu4$ allele in amyloid \hat{l}^2 positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
126	Epilepsy in neuropathologically verified Alzheimer's disease. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 9-12.	0.9	17

#	Article	IF	CITATIONS
127	Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimer's and Dementia, 2018, 14, 263-270.	0.4	236
128	Association of Cerebral Amyloid- \hat{l}^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
129	World Wide Fingers will advance dementia prevention. Lancet Neurology, The, 2018, 17, 27.	4.9	46
130	The Effect of a 2-Year Intervention Consisting of Diet, Physical Exercise, Cognitive Training, and Monitoring of Vascular Risk on Chronic Morbidityâ€"the FINGER Randomized Controlled Trial. Journal of the American Medical Directors Association, 2018, 19, 355-360.e1.	1,2	48
131	O3â€05â€05: EFFECTS OF A MULTIDOMAIN LIFESTYLE INTERVENTION ON OVERALL RISK FOR DEMENTIA: THE FINGER RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2018, 14, P1024.	0.4	5
132	Healthy Dietary Changes in Midlife Are Associated with Reduced Dementia Risk Later in Life. Nutrients, 2018, 10, 1649.	1.7	24
133	P1â€251: CSFâ€NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER. Alzheimer's and Dementia, 2018, 14, P376.	s 0.4	0
134	Copy number loss in SFMBT1 is common among Finnish and Norwegian patients with iNPH. Neurology: Genetics, 2018, 4, e291.	0.9	14
135	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
136	Associations between Prospective and Retrospective Subjective Memory Complaints and Neuropsychological Performance in Older Adults: The Finger Study. Journal of the International Neuropsychological Society, 2018, 24, 1099-1109.	1,2	11
137	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	1.7	29
138	Sleep disturbances and dementia risk: A multicenter study. Alzheimer's and Dementia, 2018, 14, 1235-1242.	0.4	85
139	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	1.2	19
140	Melatonin receptor type 1A gene linked to Alzheimer's disease in old age. Sleep, 2018, 41, .	0.6	30
141	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. Scientific Reports, 2018, 8, 11592.	1.6	41
142	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	1.7	21
143	Midlife Work-Related Stress Increases Dementia Risk in Later Life: The CAIDE 30-Year Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2017, 72, gbw043.	2.4	34
144	Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Molecular Psychiatry, 2017, 22, 874-883.	4.1	98

#	Article	lF	Citations
145	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5 . 8	250
146	Cardiorespiratory fitness and brain volumes in men and women in the FINGER study. Age and Ageing, 2017, 46, 310-313.	0.7	11
147	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
148	Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study. Maturitas, 2017, 98, 7-13.	1.0	47
149	The Modified Frontal Behavioral Inventory (FBI-mod) for Patients with Frontotemporal Lobar Degeneration, Alzheimer's Disease, and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 56, 1241-1251.	1.2	12
150	Postmenopausal hormone therapy and Alzheimer disease. Neurology, 2017, 88, 1062-1068.	1.5	98
151	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.4	32
152	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	0.9	20
153	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. Alzheimer's Research and Therapy, 2017, 9, 31.	3.0	36
154	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. Neurolmage: Clinical, 2017, 15, 613-624.	1.4	38
155	Decreased plasma βâ€amyloid in the Alzheimer's disease <scp><i>APP</i></scp> <scp>A</scp> 673 <scp>T</scp> variant carriers. Annals of Neurology, 2017, 82, 128-132.	2.8	39
156	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
157	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	1.2	72
158	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
159	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
160	Estradiol and Cognition in the Cardiovascular Risk Factors, Aging andÂDementia (CAIDE) Cohort Study. Journal of Alzheimer's Disease, 2017, 56, 453-458.	1.2	10
161	Tolerability of ORMâ€12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 1-9.	1.8	17
162	Alzheimer's Disease-Related Polymorphisms in Shunt-Responsive Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2017, 60, 1077-1085.	1,2	8

#	Article	lF	Citations
163	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
164	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	1.2	24
165	Genetic risk factors in Finnish patients with Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 39-43.	1.1	19
166	Midlife work-related stress is associated with late-life cognition. Journal of Neurology, 2017, 264, 1996-2002.	1.8	27
167	Why Does the Health-Related Quality of Life in Idiopathic Normal-Pressure Hydrocephalus Fail to Improve Despite the Favorable Clinical Outcome?. World Neurosurgery, 2017, 108, 356-366.	0.7	4
168	Nutrient intake and dietary changes during a 2-year multi-domain lifestyle intervention among older adults: secondary analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) randomised controlled trial. British Journal of Nutrition, 2017, 118, 291-302.	1.2	31
169	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
170	[P1â€"019]: MULTIDOMAIN LIFESTYLE INTERVENTION BENEFITS A LARGE ELDERLY POPULATION AT RISK FOR COGNITIVE DECLINE: SUBGROUP ANALYSES OF THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P239.	0.4	0
171	[P1–616]: DIETARY INTERVENTION ADHERENCE AND COGNITIVE CHANGES AMONG INDIVIDUALS WITH ELEVATED RISK OF DEMENTIA: THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P532.	0.4	1
172	[P1–573]: SERUM INSULIN AND THE RISK OF DEMENTIA AND COGNITIVE DECLINE: A LONGITUDINAL POPULATIONâ€BASED STUDY. Alzheimer's and Dementia, 2017, 13, P514.	0.4	0
173	Development and Validation of an Interactive Internet Platform for Older People: The Healthy Ageing Through Internet Counselling in the Elderly Study. Telemedicine Journal and E-Health, 2017, 23, 96-104.	1.6	36
174	Healthâ€related qualityâ€ofâ€life outcome in patients with idiopathic normalâ€pressure hydrocephalus – a 1â€year followâ€up study. European Journal of Neurology, 2017, 24, 58-66.	1.7	30
175	Midlife Work-Related Stress is Associated with Late-Life Gray Matter Volume Atrophy. Journal of Alzheimer's Disease Reports, 2017, 1, 219-227.	1.2	2
176	[P1–009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P234.		0
177	[P1–071]: MULTIDOMAIN LIFESTYLE INTERVENTION BENEFITS A LARGE ELDERLY POPULATION AT RISK FOR COGNITIVE DECLINE: SUBGROUP ANALYSES OF THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P265.	0.4	O
178	[P3–464]: WAISTâ€TOâ€HIP RATIO RELATED GREY MATTER REDUCTIONS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1151.	⁶ 0.4	0
179	[P3–549]: MIDLIFE COFFEE DRINKING AND DEMENTIAâ€RELATED BRAIN CHANGES ON MRI UP TO 28 YEARS LATER. Alzheimer's and Dementia, 2017, 13, P1188.	0.4	O
180	[P3–572]: MULTIMODAL LIFESTYLE AND NUTRITIONAL INTERVENTION IN PRODROMAL ALZHEIMER's DISEASE: MINDâ€AD Sub>MINI/sub> PILOT TRIAL. Alzheimer's and Dementia, 2017, 13, P1198.	0.4	0

#	Article	IF	Citations
181	[P3–573]: HEALTHY AGEING THROUGH INTERNET COUNSELLING IN THE ELDERLY (HATICE): AN ONGOING RANDOMISED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P1198.	0.4	1
182	[P3–574]: ASSOCIATIONS OF LEUCOCYTE TELOMERE LENGTH WITH BRAINÂMRIÂAND PIBâ€PET MEASURES: THEÂFINGER STUDY. Alzheimer's and Dementia, 2017, 13, P1199.	0.4	0
183	[P3–579]: IMPACT OF BASELINE BRAIN MRI MEASURES ON COGNITIVE EFFECTS OF A MULTIDOMAIN INTERVENTION: THE FINGER RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P1202.	0.4	0
184	[P3–581]: THE IMPACT OF ADHERENCE TO MULTIDOMAIN LIFESTYLE INTERVENTION ON COGNITION: THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P1203.	0.4	0
185	[P1â€"326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.4	0
186	Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial. Journal of Alzheimer's Disease, 2017, 59, 1459-1470.	1.2	20
187	Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, andÂcognition. Journal of Alzheimer's Disease, 2017, 59, 695-705.	1.2	44
188	Improving data sharing in research with context-free encoded missing data. PLoS ONE, 2017, 12, e0182362.	1.1	3
189	Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	1.1	38
190	DHCR24 exerts neuroprotection upon inflammation-induced neuronal death. Journal of Neuroinflammation, 2017, 14, 215.	3.1	34
191	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	3.0	43
192	A Multi-Cohort Study of ApoE É>4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	1.2	36
193	Targeted Serum Metabolite Profiling Identifies Metabolic Signatures in Patients with Alzheimer's Disease, Normal Pressure Hydrocephalus and Brain Tumor. Frontiers in Neuroscience, 2017, 11, 747.	1.4	14
194	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	1.2	30
195	Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. BMJ Open, 2016, 6, e010806.	0.8	7 5
196	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 313-329.	0.6	12
197	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
198	P3-030: White Matter Changes on Diffusion Tensor Imaging in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)., 2016, 12, P828-P828.		0

#	Article	IF	CITATIONS
199	P1-069: Influence of Apoe, Age, Sex, Education and Baseline Cognition on Intervention Effects on Cognition in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)., 2016, 12, P428-P429.		O
200	DTâ€01â€04: Effects of Fortasyn Connect (Souvenaid) on Longitudinal Brain Atrophy Measures in Prodromal Alzheimer's Disease: Results of the Doubleâ€Blind Randomised Controlled Lipididiet Trial. Alzheimer's and Dementia, 2016, 12, P1135.	0.4	2
201	P4â€392: Healthy Ageing Through Internet Counselling in the Elderly (HATICE): an Ongoing Randomised Controlled Trial. Alzheimer's and Dementia, 2016, 12, P1187.	0.4	3
202	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	0.8	44
203	Differential diagnosis of neurodegenerative diseases using structural MRI data. Neurolmage: Clinical, 2016, 11, 435-449.	1.4	137
204	SEPT8 modulates \hat{I}^2 -amyloidogenic processing of APP via affecting the sorting and accumulation of BACE1. Journal of Cell Science, 2016, 129, 2224-38.	1.2	15
205	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
206	Familial idiopathic normal pressure hydrocephalus. Journal of the Neurological Sciences, 2016, 368, 11-18.	0.3	30
207	High Risk of Dementia in Ventricular Enlargement with Normal Pressure Hydrocephalus Related Symptoms1. Journal of Alzheimer's Disease, 2016, 52, 497-507.	1.2	36
208	Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2016, 55, 995-1003.	1.2	6
209	Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2016, 158, 2311-2319.	0.9	21
210	Development of a Late-Life Dementia Prediction Index with Supervised Machine Learning in the Population-Based CAIDE Study. Journal of Alzheimer's Disease, 2016, 55, 1055-1067.	1.2	27
211	Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers' wellâ€being: ALSOVA 3â€year followâ€up. International Journal of Geriatric Psychiatry, 2016, 31, 273-283.	1.3	32
212	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	2.3	39
213	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	1.5	115
214	Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models. Neurobiology of Disease, 2016, 85, 187-205.	2.1	27
215	Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e55.	2.1	116
216	The Expression of Transthyretin and Amyloid- \hat{l}^2 Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2015, 48, 959-968.	1,2	19

#	Article	IF	Citations
217	Amyloid- \hat{I}^2 and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	1.2	39
218	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	1.2	31
219	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	1.2	2
220	Healthâ€related quality of life in patients with idiopathic normal pressure hydrocephalus. European Journal of Neurology, 2015, 22, 1391-1399.	1.7	21
221	Practical cutâ€offs for visual rating scales of medial temporal, frontal and posterior atrophy in <scp>A</scp> lzheimer's disease and mild cognitive impairment. Journal of Internal Medicine, 2015, 278, 277-290.	2.7	91
222	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	0.7	22
223	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease, 2015, 49, 659-669.	1.2	43
224	Midlife CAIDE Dementia Risk Score and Dementia-Related Brain Changes up to 30 Years Later on Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2015, 44, 93-101.	1.2	36
225	Circulating Proteomic Signatures of Chronological Age. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 809-816.	1.7	106
226	Impaired mitochondrial energy metabolism in Alzheimer's disease: Impact on pathogenesis via disturbed epigenetic regulation of chromatin landscape. Progress in Neurobiology, 2015, 131, 1-20.	2.8	74
227	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. Journal of Alzheimer's Disease, 2015, 45, 851-864.	1.2	10
228	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
229	Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Translational Psychiatry, 2015, 5, e494-e494.	2.4	105
230	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
231	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.4	162
232	A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet, The, 2015, 385, 2255-2263.	6.3	2,307
233	Risk prediction models in dementia prevention. Nature Reviews Neurology, 2015, 11, 375-377.	4.9	28
234	Feasibility of radiological markers in idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2015, 157, 1709-1719.	0.9	40

#	Article	IF	CITATIONS
235	Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, 2015, 5, e584-e584.	2.4	39
236	Delphi definition of the EADCâ€ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimer's and Dementia, 2015, 11, 126-138.	0.4	123
237	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. Brain Topography, 2015, 28, 746-759.	0.8	69
238	Synaptic dysfunction and septin protein family members in neurodegenerative diseases. Molecular Neurodegeneration, 2015, 10, 16.	4.4	95
239	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
240	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nature Genetics, 2015, 47, 445-447.	9.4	283
241	Targeting Prodromal Alzheimer Disease With Avagacestat. JAMA Neurology, 2015, 72, 1324.	4.5	179
242	Genetic Variation in δ-Opioid Receptor Associates with Increased β- and γ-Secretase Activity in the Late Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 507-516.	1.2	16
243	Alzheimer's disease: a report from the 7th Kuopio Alzheimer symposium. Neurodegenerative Disease Management, 2015, 5, 379-382.	1.2	22
244	The CAIDE Dementia Risk Score App: The development of an evidenceâ€based mobile application to predict the risk of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 328-333.	1.2	61
245	Hospital admissions, outpatient visits and healthcare costs of communityâ€dwellers with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 955-963.	0.4	30
246	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
247	Leisureâ€time physical activity from midâ€to late life, body mass index, and risk of dementia. Alzheimer's and Dementia, 2015, 11, 434.	0.4	163
248	FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry, 2015, 20, 1197-1204.	4.1	33
249	Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and inÂvitro models. Neurobiology of Aging, 2015, 36, 1221.e15-1221.e28.	1.5	55
250	Feelings of Hopelessness in Midlife and Cognitive Health in Later Life: A Prospective Population-Based Cohort Study. PLoS ONE, 2015, 10, e0140261.	1.1	21
251	Predicting Progression of Alzheimer's Disease Using Ordinal Regression. PLoS ONE, 2014, 9, e105542.	1.1	44
252	Recruitment and Baseline Characteristics of Participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)—A Randomized Controlled Lifestyle Trial. International Journal of Environmental Research and Public Health, 2014, 11, 9345-9360.	1.2	69

#	Article	IF	Citations
253	Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Frontiers in Cellular Neuroscience, 2014, 8, 214.	1.8	22
254	Oophorectomy, Hysterectomy, and Risk of Alzheimer's Disease: A Nationwide Case-Control Study. Journal of Alzheimer's Disease, 2014, 42, 575-581.	1.2	30
255	Behavioural and ERP effects of paradigm complexity on visual word recognition. Language, Cognition and Neuroscience, 2014, 29, 1295-1310.	0.7	5
256	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. NeuroImage: Clinical, 2014, 6, 115-125.	1.4	233
257	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	3.9	7 5
258	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	1.1	91
259	Alzheimer's diseaseâ€related plaques in nondemented subjects. Alzheimer's and Dementia, 2014, 10, 522-529.	0.4	8
260	Future directions in Alzheimer's disease from risk factors to prevention. Biochemical Pharmacology, 2014, 88, 661-670.	2.0	181
261	Validity of dementia and Alzheimer's disease diagnoses in Finnish national registers. Alzheimer's and Dementia, 2014, 10, 303-309.	0.4	103
262	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	1.5	9
263	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.4	180
264	Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort. Journal of Alzheimer's Disease, 2014, 39, 49-61.	1.2	21
265	Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down's Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
266	Late-life cynical distrust, risk of incident dementia, and mortality in a population-based cohort. Neurology, 2014, 82, 2205-2212.	1.5	22
267	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's and Dementia, 2014, 10, 456-467.	0.4	16
268	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.4	182
269	Heart Diseases and Long-Term Risk of Dementia and Alzheimer's Disease: A Population-Based CAIDE Study. Journal of Alzheimer's Disease, 2014, 42, 183-191.	1.2	155
270	Modifiable Lifestyle Factors in Dementia: A Systematic Review of Longitudinal Observational Cohort Studies. Journal of Alzheimer's Disease, 2014, 42, 119-135.	1.2	125

#	Article	IF	Citations
271	High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. Journal of Nutritional Biochemistry, 2014, 25, 634-641.	1.9	50
272	Prognostic Polypeptide Blood Plasma Biomarkers of Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2014, 40, 659-666.	1.2	44
273	A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 715-717.	1.2	30
274	Effects of Alzheimer's Disease-Associated Risk Loci on Cerebrospinal Fluid Biomarkers and Disease Progression: A Polygenic Risk Score Approach. Journal of Alzheimer's Disease, 2014, 43, 565-573.	1.2	49
275	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. Journal of Alzheimer's Disease, 2014, 39, 679-690.	1.2	35
276	P4-351: A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS. , 2014, 10, P916-P917.		0
277	Increased \hat{I}^3 -Secretase Activity in Idiopathic Normal Pressure Hydrocephalus Patients with \hat{I}^2 -Amyloid Pathology. PLoS ONE, 2014, 9, e93717.	1.1	12
278	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
279	Coronary Heart Disease and Cortical Thickness, Gray Matter and White Matter Lesion Volumes on MRI. PLoS ONE, 2014, 9, e109250.	1.1	14
280	Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Experimental Gerontology, 2013, 48, 1428-1435.	1.2	99
281	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
282	The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress. Alzheimer's and Dementia, 2013, 9, 657-665.	0.4	385
283	CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 446-458.	0.6	7
284	Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool. PLoS ONE, 2013, 8, e55246.	1.1	31
285	Hippocampal atrophy rate using an expectation maximization classifier with a disease-specific prior. , 2012, , .		1
286	Cortical Brain Biopsy in Long-Term Prognostication of 468 Patients with Possible Normal Pressure Hydrocephalus. Neurodegenerative Diseases, 2012, 10, 166-169.	0.8	56
287	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy., 2012, 8, P83-P84.		0
288	Software Tool for Improved Prediction of Alzheimer's Disease. Neurodegenerative Diseases, 2012, 10, 149-152.	0.8	14

#	Article	IF	Citations
289	Structural MRI in Frontotemporal Dementia: Comparisons between Hippocampal Volumetry, Tensor-Based Morphometry and Voxel-Based Morphometry. PLoS ONE, 2012, 7, e52531.	1.1	49
290	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology, 2012, 78, 1568-1575.	1.5	208
291	Alzheimer's Diseaseâ€Associated Ubiquilinâ€1 Regulates Presenilinâ€1 Accumulation and Aggresome Formation. Traffic, 2011, 12, 330-348.	1.3	69
292	Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation. Communicative and Integrative Biology, 2011, 4, 428-432.	0.6	6
293	Effect of APOE $\hat{l}\mu 4$ Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	1.2	82
294	O2-02-01: Prediction of Alzheimer's disease by beta-amyloid plaques and tau protein in frontal cortical biopsy., 2010, 6, S97-S97.		0
295	Apolipoprotein E É>4 magnifies lifestyle risks for dementia: a populationâ€based study. Journal of Cellular and Molecular Medicine, 2008, 12, 2762-2771.	1.6	287
296	Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience. Dementia and Geriatric Cognitive Disorders, 2008, 26, 343-350.	0.7	148
297	Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurology, The, 2006, 5, 735-741.	4.9	822
298	Response to letter by Bullock and Truyen. International Journal of Geriatric Psychiatry, 2005, 20, 87-89.	1.3	1
299	Mitochondrial DNA polymorphisms as risk factors for Parkinson?s disease and Parkinson?s disease dementia. Human Genetics, 2004, 115, 29-35.	1.8	113
300	Regional Distribution of α-Synuclein Pathology in Unimpaired Aging and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 363-367.	0.9	109
301	Vascular risk factors, ApoE ?4 allele, and gender and the risk of Alzheimer's disease: perspectives on prevention. Drug Development Research, 2002, 56, 85-94.	1.4	9
302	Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ: British Medical Journal, 2001, 322, 1447-1451.	2.4	1,298
303	Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. International Journal of Geriatric Psychiatry, 2001, 16, 1104-1106.	1.3	6
304	Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study. Annals of Neurology, 2000, 47, 470-476.	2.8	195
305	Severity of Cardiovascular Disease, Apolipoprotein E Genotype, and Brain Pathology in Aging and Dementia. Annals of the New York Academy of Sciences, 2000, 903, 244-251.	1.8	39
306	Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study. Annals of Neurology, 2000, 47, 470-476.	2.8	2

#	ARTICLE	IF	CITATIONS
307	Remodeling of neuronal circuitries in human temporal lobe epilepsy: Increased expression of highly polysialylated neural cell adhesion molecule in the hippocampus and the entorhinal cortex. Annals of Neurology, 1998, 44, 923-934.	2.8	155
308	Age-Associated Memory Impairment. Drugs and Aging, 1997, 11, 480-489.	1.3	34
309	Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ϵ4 allele. Neurology, 1995, 45, 391-392.	1.5	126